Achaogen Inc. (NASDAQ:AKAO) shares fell 4.4% during trading on Tuesday . The company traded as low as $3.67 and last traded at $3.70, with a volume of 168,540 shares trading hands. The stock had previously closed at $3.87.

A number of research firms have recently commented on AKAO. Zacks Investment Research raised shares of Achaogen from a “hold” rating to a “buy” rating and set a $4.50 price objective for the company in a research note on Wednesday, July 6th. Wedbush raised shares of Achaogen from a “neutral” rating to an “outperform” rating and upped their price objective for the company from $7.00 to $10.00 in a research note on Tuesday, June 14th. Needham & Company LLC reaffirmed a “hold” rating on shares of Achaogen in a research note on Monday, May 9th. Finally, Cowen and Company downgraded shares of Achaogen from an “outperform” rating to a “market perform” rating in a research note on Thursday, March 31st. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $10.63.

The firm’s market capitalization is $68.85 million. The stock has a 50 day moving average price of $3.84 and a 200-day moving average price of $3.75.

Achaogen, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterials to treat multi-drug resistant (MDR) gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant enterobacteriaceae (CRE).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.